MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 540081 | Name: Clofibric acid
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Clofibric acid is a PPARα agonist, auxin inhibitor and metabolite of clofibrate used as a plant growth regulator. It also decreases production of cholesterol and activity of HMG-CoA reductase and ACAT. It also suppresses microvessel growth in ovarian cancer models.

Chemical Structure

Clofibric acid
Clofibric acid
CAS#882-09-7

Theoretical Analysis

MedKoo Cat#: 540081

Name: Clofibric acid

CAS#: 882-09-7

Chemical Formula: C10H11ClO3

Exact Mass: 214.0397

Molecular Weight: 214.64

Elemental Analysis: C, 55.96; H, 5.17; Cl, 16.52; O, 22.36

Price and Availability

Size Price Availability Quantity
5g USD 250.00 2 Weeks
25g USD 450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
BRN 1874067; BRN-1874067; BRN1874067; CCRIS 9254; CCRIS-9254; CCRIS9254 Chlorfibrinic acid; NSC 1149; NSC1149; NSC-1149
IUPAC/Chemical Name
2-(4-chlorophenoxy)-2-methylpropanoic acid
InChi Key
TXCGAZHTZHNUAI-UHFFFAOYSA-N
InChi Code
InChI=1S/C10H11ClO3/c1-10(2,9(12)13)14-8-5-3-7(11)4-6-8/h3-6H,1-2H3,(H,12,13)
SMILES Code
CC(C)(OC1=CC=C(Cl)C=C1)C(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Clofibric acid (Chlorofibrinic acid), the pharmaceutically active metabolite of lipid regulators Clofibrate, Etofibrate and Etofyllinclofibrate, is a PPARα agonist which exhibits hypolipidemic effects.
In vitro activity:
CA (clofibric acid) also dose-dependently inhibited cell proliferation of cultured cell lines. CA treatment increased the expression of carbonyl reductase (CR), which promotes the conversion of prostaglandin E(2) (PGE(2)) to PGF(2alpha), in implanted OVCAR-3 tumors as well as cultured cells. Reference: Mol Cancer Ther. 2007 Apr;6(4):1379-86. https://pubmed.ncbi.nlm.nih.gov/17431116/
In vivo activity:
Rats received a single pretreatment with clofibric acid (100 mg/kg, i.p.) 1 h prior to a CCl4 (1 mL/kg, p.o.) challenge, and were euthanized 24 h after the CCl4 administration. A single pretreatment with clofibric acid effectively suppressed increases in the serum aminotransferase activities and the severity of necrosis following the CCl4 challenge, whereas the pretreatment did not protect against CCl4-induced fatty liver. Reference: Food Chem Toxicol. 2020 Nov;145:111591. https://pubmed.ncbi.nlm.nih.gov/32739454/
Solvent mg/mL mM comments
Solubility
DMSO 48.3 225.17
DMF 14.0 65.23
Ethanol 29.5 137.44
PBS (pH 7.2) 0.5 2.33
Water 1.0 4.66
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 214.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Yokoyama Y, Xin B, Shigeto T, Umemoto M, Kasai-Sakamoto A, Futagami M, Tsuchida S, Al-Mulla F, Mizunuma H. Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer. Mol Cancer Ther. 2007 Apr;6(4):1379-86. doi: 10.1158/1535-7163.MCT-06-0722. PMID: 17431116. 2. Yamakawa Y, Doi T, Naitou Y, Kawai H, Mitsumoto A, Kudo N, Kawashima Y. A single pretreatment with clofibric acid attenuates carbon tetrachloride-induced necrosis, but not steatosis, in rat liver. Food Chem Toxicol. 2020 Nov;145:111591. doi: 10.1016/j.fct.2020.111591. Epub 2020 Jul 31. PMID: 32739454.
In vitro protocol:
1. Yokoyama Y, Xin B, Shigeto T, Umemoto M, Kasai-Sakamoto A, Futagami M, Tsuchida S, Al-Mulla F, Mizunuma H. Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer. Mol Cancer Ther. 2007 Apr;6(4):1379-86. doi: 10.1158/1535-7163.MCT-06-0722. PMID: 17431116.
In vivo protocol:
1. Yamakawa Y, Doi T, Naitou Y, Kawai H, Mitsumoto A, Kudo N, Kawashima Y. A single pretreatment with clofibric acid attenuates carbon tetrachloride-induced necrosis, but not steatosis, in rat liver. Food Chem Toxicol. 2020 Nov;145:111591. doi: 10.1016/j.fct.2020.111591. Epub 2020 Jul 31. PMID: 32739454.
1: Manassero A, Satuf ML, Alfano OM. Kinetic modeling of the photocatalytic degradation of clofibric acid in a slurry reactor. Environ Sci Pollut Res Int. 2015 Jan;22(2):926-37. doi: 10.1007/s11356-014-2682-5. Epub 2014 Mar 14. PubMed PMID: 24622987. 2: Giampietro L, D'Angelo A, Giancristofaro A, Ammazzalorso A, De Filippis B, Di Matteo M, Fantacuzzi M, Linciano P, Maccallini C, Amoroso R. Effect of stilbene and chalcone scaffolds incorporation in clofibric acid on PPARα agonistic activity. Med Chem. 2014;10(1):59-65. PubMed PMID: 23432317. 3: Gutierrez-Macias T, Nacheva PM. Clofibric acid and gemfibrozil removal in membrane bioreactors. Water Sci Technol. 2015;71(8):1143-50. doi: 10.2166/wst.2015.079. PubMed PMID: 25909723. 4: Gowdra VS, Mudgal J, Bansal P, Nayak PG, Manohara Reddy SA, Shenoy GG, Valiathan M, Chamallamudi MR, Nampurath GK. Synthesis, characterization, and preclinical evaluation of new thiazolidin-4-ones substituted with p-chlorophenoxy acetic acid and clofibric acid against insulin resistance and metabolic disorder. Biomed Res Int. 2014;2014:620434. doi: 10.1155/2014/620434. Epub 2014 Jun 3. PubMed PMID: 24995315; PubMed Central PMCID: PMC4065710. 5: Salgado R, Oehmen A, Carvalho G, Noronha JP, Reis MA. Biodegradation of clofibric acid and identification of its metabolites. J Hazard Mater. 2012 Nov 30;241-242:182-9. doi: 10.1016/j.jhazmat.2012.09.029. Epub 2012 Sep 24. PubMed PMID: 23062606. 6: Sun Q, Wang Y, Li L, Bing J, Wang Y, Yan H. Mechanism for enhanced degradation of clofibric acid in aqueous by catalytic ozonation over MnOx/SBA-15. J Hazard Mater. 2015 Apr 9;286:276-84. doi: 10.1016/j.jhazmat.2014.12.050. Epub 2014 Dec 30. PubMed PMID: 25590821. 7: Saravanan M, Hur JH, Arul N, Ramesh M. Toxicological effects of clofibric acid and diclofenac on plasma thyroid hormones of an Indian major carp, Cirrhinus mrigala during short and long-term exposures. Environ Toxicol Pharmacol. 2014 Nov;38(3):948-58. doi: 10.1016/j.etap.2014.10.013. Epub 2014 Oct 24. PubMed PMID: 25461555. 8: Hirose A, Yamazaki T, Sakamoto T, Sunaga K, Tsuda T, Mitsumoto A, Kudo N, Kawashima Y. Clofibric acid increases the formation of oleic acid in endoplasmic reticulum of the liver of rats. J Pharmacol Sci. 2011;116(4):362-72. Epub 2011 Jul 14. PubMed PMID: 21757842. 9: Corcoran J, Winter MJ, Lange A, Cumming R, Owen SF, Tyler CR. Effects of the lipid regulating drug clofibric acid on PPARα-regulated gene transcript levels in common carp (Cyprinus carpio) at pharmacological and environmental exposure levels. Aquat Toxicol. 2015 Apr;161:127-37. doi: 10.1016/j.aquatox.2015.01.033. Epub 2015 Feb 9. PubMed PMID: 25749508; PubMed Central PMCID: PMC4372818. 10: Hwang B, Wu P, Harris RA. Additive effects of clofibric acid and pyruvate dehydrogenase kinase isoenzyme 4 (PDK4) deficiency on hepatic steatosis in mice fed a high saturated fat diet. FEBS J. 2012 May;279(10):1883-93. doi: 10.1111/j.1742-4658.2012.08569.x. Epub 2012 Apr 4. PubMed PMID: 22429297; PubMed Central PMCID: PMC3334477. 11: Zhang DQ, Gersberg RM, Hua T, Zhu J, Ng WJ, Tan SK. Assessment of plant-driven uptake and translocation of clofibric acid by Scirpus validus. Environ Sci Pollut Res Int. 2013 Jul;20(7):4612-20. doi: 10.1007/s11356-012-1375-1. Epub 2012 Dec 30. PubMed PMID: 23274803. 12: Brox S, Seiwert B, Haase N, Küster E, Reemtsma T. Metabolism of clofibric acid in zebrafish embryos (Danio rerio) as determined by liquid chromatography-high resolution-mass spectrometry. Comp Biochem Physiol C Toxicol Pharmacol. 2016 Jul-Aug;185-186:20-8. doi: 10.1016/j.cbpc.2016.02.007. Epub 2016 Mar 3. PubMed PMID: 26945519. 13: Giampietro L, Ammazzalorso A, Bruno I, Carradori S, De Filippis B, Fantacuzzi M, Giancristofaro A, Maccallini C, Amoroso R. Synthesis of Naphthyl-, Quinolin- and Anthracenyl Analogues of Clofibric Acid as PPARα Agonists. Chem Biol Drug Des. 2016 Mar;87(3):467-71. doi: 10.1111/cbdd.12677. Epub 2015 Nov 20. PubMed PMID: 26502898. 14: Emudianughe TS, Caldwell J, Sinclair KA, Smith RL. Species differences in the metabolic conjugation of clofibric acid and clofibrate in laboratory animals and man. Drug Metab Dispos. 1983 Mar-Apr;11(2):97-102. PubMed PMID: 6133730. 15: Cayen MN, Ferdinandi ES, Greselin E, Robinson WT, Dvornik D. Clofibrate and clofibric acid: comparison of the metabolic disposition in rats and dogs. J Pharmacol Exp Ther. 1977 Jan;200(1):33-43. PubMed PMID: 833760. 16: Meffin PJ, Zilm DM, Veenendaal JR. A renal mechanism for the clofibric acid-probenecid interaction. J Pharmacol Exp Ther. 1983 Dec;227(3):739-42. PubMed PMID: 6655567. 17: Olsson U, Sundberg C, Andersson K, De Pierre JW. Further studies on the involvement of selenium in peroxisome proliferation in rat liver. Comparison of effects with clofibric acid and perfluorooctanoic acid and the pharmacokinetics of [14C]clofibrate. Biochem Pharmacol. 1993 Nov 17;46(10):1805-10. PubMed PMID: 8250967. 18: Meffin PJ, Zilm DM. The analysis of [14C]clofibric acid glucuronide and [14C]clofibric acid in plasma and urine using high-performance liquid chromatography. J Chromatogr. 1983 Nov 11;278(1):101-8. PubMed PMID: 6662867. 19: Harvengt C, Desager JP. Plasma clofibric acid (CPIB) levels induced by three marketed compounds releasing clofibric acid, in volunteers. Int J Clin Pharmacol Biopharm. 1977 Jan;15(1):1-4. PubMed PMID: 576423. 20: Dragacci S, Hamar-Hansen C, Fournel-Gigleux S, Lafaurie C, Magdalou J, Siest G. Comparative study of clofibric acid and bilirubin glucuronidation in human liver microsomes. Biochem Pharmacol. 1987 Nov 15;36(22):3923-7. PubMed PMID: 3120730.